Table 3 Clinical trials for neural stem cell transplantation
From: Current progress in the derivation and therapeutic application of neural stem cells
Conditions | Transplanted cells | Status/intervening results | Phase | Location | Start year |
|---|---|---|---|---|---|
ALS | Spinal cord-derived NSCs | Safe with unilateral and bilateral intraspinal lumbar microinjection | Phase I | United States | 2011 |
ALS | Spinal cord-derived NSCs | No study results | Phase II | United States | 2012 |
ALS | Fetal brain-derived NSCs | Improved tibialis anterior | Phase I | Italy | 2012 |
ALS | CNS10-NPC-GDNF | Recruiting | Phase I | United States | 2016 |
PD | Parthenogenetic stem cell-derived NSCs | Recruiting | Phase I | Australia | 2015 |
PD | ESCs-derived NPCs | Recruiting | Phase I/II | China | 2017 |
PD | Fetal brain-derived NSCs | Invitation | Phase II/III | China | 2017 |
MS | MSCs-derived NPCs | Active, not recruiting | Phase I | United States | 2013 |
SCI | Fetal brain-derived NSPCs | Safe and well-tolerated | Phase I/II | Korea | 2005 |
SCI | MSCs-derived NSCs | Active, not recruiting | Phase I/II | Russia | 2014 |
SCI | Spinal cord-derived NSCs | Recruiting | Phase I | United States | 2013 |
SCI | CNS stem cells | Terminated, no study results | Phase II | United States, Canada | 2014 |
SCI | NSCs combined with Scaffold | Recruiting | Phase I/II | China | 2016 |
SCI | CNS stem cells | No study results | Phase I/II | Canada, Switzerland | 2011 |
Stroke | CTX0E03 | Improved neurological function with no adverse events | Phase I | United Kingdom | 2010 |
Stroke | CTX0E03 | Active, not recruiting | Phase II | United Kingdom | 2014 |
CP | Fetal brain-derived NPCs | Improvement of functional development and no delayed complications | NA | China | 2005 |
CP | Fetal brain-derived NSCs | Improvement with varying degrees and no severe adverse reactions | NA | China | 2005 |
CP | Bone marrow MSCs- derived NSCs-like cells | Optimal improvement in motor function | NA | China | 2010 |
CP | NSCs | Active, not recruiting | NA | China | 2016 |
HIE | NPCs with paracrine factors from MSCs | Recruiting | NA | China | 2014 |
MD | CNS stem cells | No study results | Phase I/II | United States | 2012 |
LLI | CTX0E03 | Active, not recruiting | Phase I | United Kingdom | 2013 |
Glioma | NSCs expressing E. Coli CD | No study results | Phase I | United States | 2010 |
Glioma | NSCs expressing E. Coli CD | Recruiting | Phase I | United States | 2013 |
Glioma | NSCs expressing Carboxylesterase | Recruiting | Phase I | United States | 2014 |
Glioma | NSCs loaded with oncolytic adenovirus | Recruiting | Phase I | United States | 2017 |
GBM | NPCs | Active, not recruiting | Phase I | United States | 2011 |
IBM | NSCs | Terminated, no study results | Phase III | United States | 2007 |
